[go: up one dir, main page]

AR074184A1 - Compuestos de 7-azaspiro[3.5]nonano-7-carboxamida, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de afecciones mediadas por la inhibicion de faah - Google Patents

Compuestos de 7-azaspiro[3.5]nonano-7-carboxamida, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de afecciones mediadas por la inhibicion de faah

Info

Publication number
AR074184A1
AR074184A1 ARP090104209A ARP090104209A AR074184A1 AR 074184 A1 AR074184 A1 AR 074184A1 AR P090104209 A ARP090104209 A AR P090104209A AR P090104209 A ARP090104209 A AR P090104209A AR 074184 A1 AR074184 A1 AR 074184A1
Authority
AR
Argentina
Prior art keywords
alkyl
haloalkyl
optionally substituted
haloalkoxy
alkoxy
Prior art date
Application number
ARP090104209A
Other languages
English (en)
Inventor
Scott Allen Long
Marvin Jay Meyers
Lijuan Jane Wang
Atli Thorarensen
Matthew James Pelc
Barbara Ann Schweitzer
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR074184A1 publication Critical patent/AR074184A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)

Abstract

Se proporcionan compuestos de 7-azaspiro[3.5]nonano-7-carboxamida y las sales farmacéuticamente aceptables de tales compuestos utiles en el tratamiento de enfermedades o afecciones asociadas a la actividad de hidrolasa de amidas de ácidos grasos (FAAH), incluyendo las afecciones dolor agudo, dolor cronico, dolor neuropático, dolor nociceptivo, dolor inflamatorio, cáncer y dolor del cáncer, fibromialgia, artritis reumatoide, enfermedad inflamatoria del intestino, lupus, diabetes, asma alérgica, inflamacion vascular, incontinencia urinaria, hiperactividad vesical, emesis, trastornos cognitivos, ansiedad, depresion, trastornos del sueno, trastornos de la alimentacion, trastornos del movimiento, glaucoma, psoriasis, esclerosis multiple, trastornos cerebrovasculares, lesion cerebral, trastornos gastrointestinales, hipertension o enfermedad cardiovascular. Reivindicacion 1: Un compuesto caracterizado porque es de formula (1), en el que: Ar1 se selecciona entre: los compuesto a) a e) del grupo de formulas (2); f) benzoisoxazol opcionalmente sustituido por de 1 a 3 sustituyentes seleccionados entre halo, alquilo C1-3, alcoxi C1-3, haloalquilo C1-3 o haloalcoxi C1-3; o g) piridina, piridazina, pirimidina, o pirazina; en los que la piridina, piridazina, pirimidina o pirazina se sustituye opcionalmente por de 1 a 3 sustituyentes halo, alquilo C1-3, -(CH2)n-(cicloalquilo C3-6), alcoxi C1-3, haloalquilo C1-3 o haloalcoxi C1-3; Ar2 se selecciona entre: a) fenilo opcionalmente sustituido por de 1 a 5 sustituyentes seleccionados entre halo, alquilo C1-6, -(CH2)n-(cicloalquilo C3-6), alcoxi C1-6, -(CH2)n(cicloalcoxi C3-6), haloalquilo C1-6, haloalcoxi C1-6, -O-CH2-CH2-O-(alquilo C1-6), o -O-CH2-CH2-O-(haloalquilo C1-6); en los que el fenilo se sustituye opcionalmente por un sustituyente de las formulas -R9, -O-R9, -O-(CH2)p-R9, o -(CH2)p-O-R9; b) oxazol, isoxazol, tiazol, isotiazol, oxadiazol o tiadiazol sustituido por un sustituyente de las formulas -(CH2)n-R9, -(CH2)m-O-R9, o -(CH2)p-O-(CH2)p-R9; c) un heterociclo de la formula (3), en el que X es CH2 o O, y W es (CH2)m o CF2; o d) naftilo, quinolinilo o isoquinolinilo opcionalmente sustituido por de 1 a 3 sustituyentes halo, alquilo C1-3, alcoxi C1-3, haloalquilo C1-3 o haloalcoxi C1-3; en los que si Ar1 es piridina, piridazina, pirimidina, o pirazina, entonces Ar2 debe ser un anillo de fenilo sustituido por -O-R9; R1 y R2 se seleccionan independientemente entre hidrogeno, F o CH3; R3 es hidrogeno, CH3, -O-CH3, OH, CN o F; R4 es hidrogeno, alquilo C1-6, -(CH2)n-(cicloalquilo C3-6) o haloalquilo C1-6; R5 es alquilo C1-3; R6 es hidrogeno, alquilo C1-6 o haloalquilo C1-3; R7 es alquilo C1-3, -(CH2)n-(cicloalquilo C3-6), R9 o -CH2-O-R9; R8 es fenilo opcionalmente sustituido por entre 1 y 3 sustituyentes seleccionados entre los grupos halo, alquilo C1-3, alcoxi C1-3, haloalquilo C1-3 o haloalcoxi C1-3; R9 se selecciona entre fenilo, naftilo o heteroarilo; en el que R9 se sustituye opcionalmente por entre 1 y 3 sustituyentes seleccionados entre halo, alquilo C1-3, -(CH2)n-(cicloalquilo C3-6), alcoxi C1-3, -(CH2)n-(cicloalcoxi C3-6), haloalquilo C1-3, o haloalcoxi C1-3; m es 1, 2 o 3; n es 0, 1, 2, 3 o 4; y p es 1 o 2; o su sal farmacéuticamente aceptable.
ARP090104209A 2008-10-30 2009-10-30 Compuestos de 7-azaspiro[3.5]nonano-7-carboxamida, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de afecciones mediadas por la inhibicion de faah AR074184A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10971208P 2008-10-30 2008-10-30
US12134908P 2008-12-10 2008-12-10

Publications (1)

Publication Number Publication Date
AR074184A1 true AR074184A1 (es) 2010-12-29

Family

ID=41560876

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104209A AR074184A1 (es) 2008-10-30 2009-10-30 Compuestos de 7-azaspiro[3.5]nonano-7-carboxamida, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de afecciones mediadas por la inhibicion de faah

Country Status (8)

Country Link
US (1) US20100113465A1 (es)
EP (1) EP2358704A1 (es)
JP (1) JP2012507500A (es)
AR (1) AR074184A1 (es)
CA (1) CA2738776A1 (es)
TW (1) TW201022257A (es)
UY (1) UY32205A (es)
WO (1) WO2010049841A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100130477A1 (en) * 2008-11-25 2010-05-27 Astrazeneca Ab Spirocyclobutyl Piperidine Derivatives
FR2941696B1 (fr) * 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
US20130029978A1 (en) 2009-12-25 2013-01-31 Mochida Pharmaceutical Co., Ltd. Novel aryl urea derivative
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
US9822129B2 (en) 2012-03-02 2017-11-21 Genentech, Inc. Amido spirocyclic amide and sulfonamide derivatives
EP2903985A1 (en) * 2012-10-03 2015-08-12 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN104059041B (zh) * 2013-03-20 2018-10-16 上海方楠生物科技有限公司 抗糖尿病药物达格列净中间体的制备方法
PT3174858T (pt) 2014-07-31 2019-07-23 Basf Se Processo para preparar pirazoles
KR20240033160A (ko) 2015-05-11 2024-03-12 바스프 에스이 4-아미노-피리다진의 제조 방법
WO2018082964A1 (en) 2016-11-04 2018-05-11 Basf Se Process for the production of pyridazinyl-amides in a one-pot synthesis
JP7408064B2 (ja) * 2017-08-21 2024-01-05 マイクロバイオティックス， インク． 抗菌剤として有用な代謝的に安定したｎ－アシルアミノオキサジアゾール
TWI767148B (zh) * 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020077071A1 (en) * 2018-10-10 2020-04-16 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (fasn)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
RS56194B1 (sr) * 2004-12-30 2017-11-30 Janssen Pharmaceutica Nv Derivativi fenilamida 4-(benzil)-piperazin-1-karboksilne kiseline i slična jedinjenja kao modulatori hidrolaze amida masnih kiselina (faah) za lečenje anksioznosti, bola i ostalih stanja
TWI363161B (en) * 2006-07-26 2012-05-01 Ind Tech Res Inst Light emitting diode lighting module with improved heat dissipation structure

Also Published As

Publication number Publication date
JP2012507500A (ja) 2012-03-29
WO2010049841A1 (en) 2010-05-06
CA2738776A1 (en) 2010-05-06
US20100113465A1 (en) 2010-05-06
UY32205A (es) 2010-05-31
TW201022257A (en) 2010-06-16
EP2358704A1 (en) 2011-08-24

Similar Documents

Publication Publication Date Title
AR074184A1 (es) Compuestos de 7-azaspiro[3.5]nonano-7-carboxamida, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de afecciones mediadas por la inhibicion de faah
JP6630771B2 (ja) Ｍｅｋインヒビターとしてのヘテロシクリル化合物
AU2008318491B2 (en) Cytokine inhibitors
TWI548616B (zh) 巨大戟萜醇－３－醯化物iii及巨大戟萜醇－３－胺基甲酸酯化物
JP2024129146A (ja) Ｃ－ｋｉｔ阻害剤としてのアミノチアゾール化合物
TWI538905B (zh) 雙環［３．２．１］辛基醯胺衍生物及其用途
HRP20170695T1 (hr) Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka
AR059895A1 (es) Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos
RU2009142431A (ru) Производные триазолопиридинкарбоксамидов и триазолопиримидинкарбоксамидов, их получение и их применение в терапии
AR069545A1 (es) Derivados de aril y heteroarilcarbonilo de benzomorfanos y estructuras relacionadas, composiciones farmaceuticas que contienen dichos compuestos, obtencion de las mismas, su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa (hsd) 1 y
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
WO2009127944A8 (en) Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors
CO6251251A2 (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
AR065464A1 (es) Derivados de nicotinamida. composiciones farmaceuticas
TW201938166A (zh) 帽依賴性核酸內切酶抑制劑
AR045651A1 (es) Derivados de tiazol como moduladores del receptor de cannabinoide
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
BRPI0719861A2 (pt) Compostos heteroaromáticos bicíclicos
AR072353A1 (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como modula-dores de leucotrieno a4 hidrolasa
AR051290A1 (es) Derivados de hidantoina sustituidas
JP7017787B2 (ja) ユビキチン化－プロテアソーム系に関連する化合物および薬学的組成物
AR075951A1 (es) Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek
JP2015502371A5 (es)
WO2011140164A1 (en) Aza-indole derivatives useful as modulators of faah

Legal Events

Date Code Title Description
FA Abandonment or withdrawal